Sign up to save your podcasts
Or
Share The Lancet: March 25, 2008
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Lancet: March 25, 2008
Josef Smolen from the Medical University of Vienna, Austria, discusses in this week's podcast how the monoclonal antibody tocilizumab could be effective in treating rheumatoid arthritis. Tocilizumab blocks interleukin 6, a pro-inflammatory cytokine involved in the biological process behind rheumatoid arthritis
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupJosef Smolen from the Medical University of Vienna, Austria, discusses in this week's podcast how the monoclonal antibody tocilizumab could be effective in treating rheumatoid arthritis. Tocilizumab blocks interleukin 6, a pro-inflammatory cytokine involved in the biological process behind rheumatoid arthritis
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet in conversation with
View all
NEJM This Week
325 Listeners
JAMA Clinical Reviews
496 Listeners
Consumer Foods to Go
5 Listeners
The Lancet Voice
23 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
2 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners